Publications & Presentations
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients with Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model
Maolin Yu, Mark W. Ledeboer, Matthew Daniels, Goran Malojcic, Thomas T. Tibbitts, Marie Coeffet-Le Gal, Xin-Ru Pan-Zhou, Amy Westerling-Bui, Maria Beconi, John F. Reilly, Peter Mundel, and Jean-Christophe Harmange
Structural basis of TRPC4 regulation by calmodulin and pharmacological agents
Deivanayagabarathy Vinayagam, Dennis Quentin, Jing Yu-Strzelczyk, Oleg Sitsel, Felipe Merino, Markus Stabrin, Oliver Hofnagel, Maolin Yu, Mark W Ledeboer, Georg Nagel, Goran Malojcic, Stefan Raunser
Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis
Jonathan P. Troost, Howard Trachtman, Cathie Spino, Frederick J. Kaskel, Aaron Friedman, Marva M. Moxey-Mims, Richard N. Fine, Jennifer J. Gassman, Jeffrey B. Kopp, Liron Walsh, Rong Wang, Debbie S. Gipson
Generation of Collecting Duct Kidney Organoids from hiPSC
Sergii Kyrychenko, Xiang Pan, Eva Maria Fast, Alyssa B. Fanelli, Henrietta Bennet, Maria Lalioti, John F. Reilly, Peter Mundel, Amy Duyen Westerling-Bui
GFB-887
Our lead product candidate, GFB-887 is designed specifically to treat people with kidney diseases associated with an over-activation of the TRPC5-1 pathway.
GFB-024
Our second product candidate is intended to treat patients with severe insulin resistant diabetic nephropathy (SIRDN) and CB1 pathway overactivation.